VCNX · Vaccinex, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $52.0K | $232.0K | $104.0K | - | $20.0K | - | $550.0K | - | $50.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $3.17M | $3.86M | $3.38M | - | $4.36M | $5.05M | $3.81M | - | $3.43M |
| SG&A | - | $1.44M | $2.09M | $1.79M | - | $1.50M | $2.03M | $1.72M | - | $1.41M |
| Total Operating Expenses | - | $4.60M | $5.95M | $5.18M | - | $5.85M | $7.08M | $5.54M | - | $4.84M |
| D&A | - | $24.0K | $25.0K | $27.0K | - | $31.0K | $30.0K | $31.0K | - | $67.0K |
| Operating Income | - | ($4.55M) | ($5.72M) | ($5.07M) | - | ($5.83M) | ($7.08M) | ($4.99M) | - | ($4.79M) |
| Interest Expense | - | - | - | - | - | - | $0 | $0 | - | $1.0K |
| Income Tax | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 |
| Net Income | - | ($5.73M) | ($5.63M) | ($3.90M) | - | ($4.91M) | ($7.06M) | ($4.96M) | - | ($4.76M) |
| EPS - Basic | - | ($2.83) | ($3.10) | ($2.94) | - | ($15.26) | ($25.20) | ($21.00) | - | ($35.70) |
| EPS - Diluted | - | ($2.83) | ($3.10) | ($2.94) | - | ($15.26) | ($25.20) | ($25.20) | - | ($35.70) |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.11M | $2.91M | $233.0K | $2.97M | $1.53M | $127.0K | $1.91M | $3.32M | $6.39M | $7.19M |
| Accounts Receivable | $838.0K | $985.0K | $1.04M | $2.77M | $961.0K | $933.0K | $11.0K | - | $175.0K | $50.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.96M | $4.87M | $3.24M | $2.33M | $2.04M | $4.22M | $1.61M | $1.09M | $1.52M | $494.0K |
| Current Assets | $2.53M | $4.76M | $2.20M | $7.15M | $3.35M | $2.21M | $2.68M | $4.42M | $7.48M | $8.03M |
| Total Assets | $2.60M | $4.85M | $2.37M | $7.37M | $3.63M | $2.56M | $3.08M | $4.89M | $7.98M | $8.61M |
| Current Liabilities | $5.08M | $6.17M | $5.23M | $4.71M | $5.92M | $6.36M | $3.38M | $2.31M | $2.54M | $1.99M |
| Long-term Debt | $0 | - | - | $6.0K | $26.0K | $44.0K | $63.0K | $82.0K | $101.0K | $119.0K |
| Total Liabilities | $5.08M | $6.17M | $5.23M | $4.71M | $5.94M | $6.43M | $3.51M | $2.50M | $2.78M | $2.29M |
| Stockholders' Equity | ($2.49M) | ($1.32M) | ($2.86M) | $2.65M | ($2.31M) | ($3.87M) | ($423.0K) | $2.40M | $5.19M | $6.32M |
| Retained Earnings | ($358.56M) | ($355.19M) | ($349.45M) | ($343.82M) | ($339.93M) | ($336.61M) | ($331.70M) | ($324.64M) | ($319.68M) | ($314.60M) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($4.63M) | - | - | - | ($5.04M) | - | - |
| Investing Cash Flow | - | - | - | $0 | - | - | - | ($49.0K) | - | - |
| Financing Cash Flow | - | - | - | $6.07M | - | - | - | $2.02M | - | - |
| CapEx | - | - | - | $0 | - | - | - | $49.0K | - | - |
| Free Cash Flow | - | - | - | ($4.63M) | - | - | - | ($5.09M) | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -8753.8% | -2466.4% | -4878.8% | - | -29170.0% | - | -906.5% | - | -9584.0% |
| EBITDA margin | - | -8707.7% | -2455.6% | -4852.9% | - | -29015.0% | - | -900.9% | - | -9450.0% |
| Net margin | - | -11023.1% | -2427.2% | -3747.1% | - | -24560.0% | - | -902.2% | - | -9518.0% |
| Free cash flow margin | - | - | - | -4453.8% | - | - | - | -925.3% | - | - |
| FCF / Net income | - | - | - | 1.19 | - | - | - | 1.03 | - | - |
| R&D / Revenue | - | 6086.5% | 1665.5% | 3252.9% | - | 21775.0% | - | 693.1% | - | 6858.0% |
| SG&A / Revenue | - | 2767.3% | 900.9% | 1726.0% | - | 7495.0% | - | 313.5% | - | 2826.0% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -118.1% | -237.9% | -52.9% | - | -192.0% | -228.8% | -101.4% | - | -55.3% |
| Return on equity | - | 433.9% | 196.6% | -146.8% | - | 127.0% | 1669.0% | -206.8% | - | -75.3% |
| Return on invested capital | - | - | - | -150.6% | - | - | - | -158.7% | - | -58.8% |
| Liquidity | ||||||||||
| Current ratio | 0.50 | 0.77 | 0.42 | 1.52 | 0.57 | 0.35 | 0.79 | 1.91 | 2.95 | 4.04 |
| Quick ratio | 0.50 | 0.77 | 0.42 | 1.52 | 0.57 | 0.35 | 0.79 | 1.91 | 2.95 | 4.04 |
| Cash ratio | 0.22 | 0.47 | 0.04 | 0.63 | 0.26 | 0.02 | 0.56 | 1.44 | 2.52 | 3.62 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | - | - | 0.00 | -0.01 | -0.01 | -0.15 | 0.03 | 0.02 | 0.02 |
| Debt / Assets | 0.00 | - | - | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | -4792.0x |
| Equity multiplier | -1.04 | -3.67 | -0.83 | 2.77 | -1.57 | -0.66 | -7.29 | 2.04 | 1.54 | 1.36 |
| Liabilities / Assets | 1.96 | 1.27 | 2.21 | 0.64 | 1.64 | 2.51 | 1.14 | 0.51 | 0.35 | 0.27 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.01 | 0.10 | 0.01 | - | 0.01 | - | 0.11 | - | 0.01 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | 6914d | 1644d | 9739d | - | 17027d | - | - | - | 365d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 3.7x | - | - | - | 1745.8x | - | 511.9x |
| P / S | - | 132.5x | 50.8x | 94.6x | - | 3564.9x | - | 7618.2x | - | 64682.3x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 160.0% | - | -81.1% | - | -60.0% | - | - | - | 0.0% |
| Revenue CAGR (3y) | - | 1.3% | - | -50.4% | - | -26.3% | - | - | - | -50.2% |
| Revenue CAGR (5y) | - | -33.6% | 56.1% | -12.8% | - | -36.8% | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 22.0% | 19.1% | -1.8% | - | -21.7% | -31.0% | -8.5% | - | 5.4% |
| Net income growth (YoY) | - | -16.7% | 20.2% | 21.5% | - | -3.2% | -31.2% | -8.0% | - | 8.6% |
| EPS growth (YoY) | - | 81.5% | 87.7% | 88.3% | - | 57.3% | -19284.6% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 9.0% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -7.7% | 65.9% | -577.1% | 10.6% | - | - | - | -85.2% | -29.9% | -46.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$500.0K totalExclusive Product License$500.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing VACCINEX against the 5 most active filers in the same SIC group.